DataSheet_2_Reversibility of Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis.pdf (29.58 kB)
Download file

DataSheet_2_Reversibility of Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis.pdf

Download (29.58 kB)
dataset
posted on 28.07.2021, 05:33 authored by Helene Speyer, Casper Westergaard, Nikolai Albert, Mette Karlsen, Anne Emilie Stürup, Merete Nordentoft, Jesper Krogh
Background and Aims

Weight gain is a major adverse effect of antipsychotic medication, negatively affecting physical and mental well-being. The objective of this study was to explore if dose reduction, discontinuation, switch to a partial agonist, or switch from polypharmacy to monotherapy will lead to weight loss.

Methods

Controlled and uncontrolled studies reporting the effects of discontinuation, dose reduction, switch to a partial agonist, or switch from polypharmacy to monotherapy on weight were included. Primary outcome was difference in weight compared to maintenance groups based on controlled studies. Secondary outcome was change in weight from initiation of one of the included interventions until follow-up in a pre-post analysis.

Results

We identified 40 randomized controlled trials and 15 uncontrolled studies including 12,279 individuals. The effect of the interventions, i.e. dose reduction, drug discontinuation, or switch to a partial agonis, reduced the weight with 1.5 kg (95% CI −2.03 to −0.98; P < 0.001) compared to maintenance treatment. The weight change from pre to post was a reduction of 1.13 kg (95% CI −1.36 to −0.90; P < 0.001).

Conclusion

We found a significant but small reduction in weight, suggesting that antipsychotic-induced weight gain can be reversed to some degree. Only a few studies were designed to address the question as primary outcome, which limits the generalizability of our findings.

History

References